Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3079% below fair value
$3.37−0.08 (-2.32%)
Close on Nov 13, 2026Market cap $236.22MP/E –Yield 0.00%
Bicycle Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Bicycle Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$153.56M. For fiscal 2025 it was -$240.64M. The highest annual figure on record is -$15.88M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$240.64M | – |
| FY2024 | Dec 31, 2024 | -$202.70M | – |
| FY2023 | Dec 31, 2023 | -$183.40M | – |
| FY2022 | Dec 31, 2022 | -$112.96M | – |
| FY2021 | Dec 31, 2021 | -$64.21M | – |
| FY2020 | Dec 31, 2020 | -$50.68M | – |
| FY2019 | Dec 31, 2019 | -$25.34M | – |
| FY2018 | Dec 31, 2018 | -$21.03M | – |
| FY2017 | Dec 31, 2017 | -$15.88M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$12.38M | – |
| Q2 FY2026 | Jun 30, 2026 | -$53.46M | – |
| Q1 FY2026 | Mar 31, 2026 | -$64.35M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.37M | – |
| Q3 FY2025 | Sep 30, 2025 | -$63.75M | – |
| Q2 FY2025 | Jun 30, 2025 | -$84.90M | – |
| Q1 FY2025 | Mar 31, 2025 | -$68.57M | – |
| Q4 FY2024 | Dec 31, 2024 | -$65.96M | – |
| Q3 FY2024 | Sep 30, 2024 | -$61.65M | – |
| Q2 FY2024 | Jun 30, 2024 | -$45.05M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.06M | – |
| Q4 FY2023 | Dec 31, 2023 | -$52.58M | – |
| Q3 FY2023 | Sep 30, 2023 | -$49.10M | – |
| Q2 FY2023 | Jun 30, 2023 | -$41.47M | – |
| Q1 FY2023 | Mar 31, 2023 | -$40.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$30.83M | – |
| Q3 FY2022 | Sep 30, 2022 | -$28.50M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.68M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.96M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.96M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.94M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.70M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.73M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.35M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.34M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.49M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.01M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.76M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.08M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.18M | – |
See a number that looks wrong?